Our results show that SMA in combination with cisplatin synergistically increased anti-tumor activity in mice xenografted with A549 NSCLC without significant alteration in body weight (S1 Fig), which suggests SMA may be a valuable adjuvant therapeutic agent in combination with lower cisplatin doses. Here, SMN1 is linked to non-small cell lung carcinoma.